Canine cognitive impairment syndrome (CDS) represents a group of symptoms related to the aging of the canine brain. These changes ultimately lead to a decline of memory function and learning abilities, alteration of social interaction, impairment of normal housetraining, and changes in sleep-wake cycle and general activity. We have clinically examined 215 dogs, 28 of which underwent autopsy. With canine brains, we performed extensive analysis of pathological abnormalities characteristic of human Alzheimer's disease and frontotemporal lobar degeneration, including β-amyloid senile plaques, tau neurofibrillary tangles, and fused in sarcoma (FUS) and TAR DNA-binding protein 43 (TDP43) inclusions. Most demented dogs displayed senile plaques, mainly in the frontal and temporal cortex. Tau neurofibrillary inclusions were found in only one dog. They were identified with antibodies used to detect tau neurofibrillary lesions in the human brain. The inclusions were also positive for Gallyas silver staining. As in humans, they were distributed mainly in the entorhinal cortex, hippocampus, and temporal cortex. On the other hand, FUS and TDP43 aggregates were not present in any of the examined brain samples. We also found that CDS was characterized by the presence of reactive and senescent microglial cells in the frontal cortex. Our transcriptomic study revealed a significant dysregulation of genes involved in neuroinflammation. Finally, we analyzed tau phosphoproteome in the synaptosomes. Proteomic studies revealed a significant increase of hyperphosphorylated tau in synaptosomes of demented dogs compared with nondemented dogs. This study suggests that cognitive decline in dogs is related to the tau synaptic impairment and neuroinflammation. J. Comp. Neurol. 524:874-895, 2016. © 2015 Wiley Periodicals, Inc.
Pubmed ID: 26239295 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets Phospho-Tau (Ser262)
View all literature mentionsThis polyclonal targets DBN1
View all literature mentionsThis monoclonal targets Actin
View all literature mentionsThis monoclonal targets Phospho-Tau (Ser396)
View all literature mentionsThis monoclonal targets Phospho-Tau (Ser202, Thr205)
View all literature mentionsThis monoclonal targets beta-Amyloid 17-24
View all literature mentionsThis polyclonal targets Phospho-Tau (Thr205)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser214)
View all literature mentionsThis polyclonal targets Iba1
View all literature mentionsThis monoclonal targets Synaptophysin 1
View all literature mentionsThis monoclonal targets Phospho-Tau (Thr231)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser404)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser199)
View all literature mentionsThis polyclonal targets Phospho-Tau (Thr212)
View all literature mentionsThis polyclonal targets Human Tau, phospho (Thr217)
View all literature mentionsThis polyclonal targets N-terminal region of human FUS isoform
View all literature mentionsBioimaging analysis software used to acquire quantitative and qualitative data from various types of biological samples. The software provides a variety of image modification features, including contrast optimizing, image printing, 1-dimensional densitometry, fragment length and molecular weight determination, and 2-D densitometry.
View all literature mentionsStatistical analysis software that combines scientific graphing, comprehensive curve fitting (nonlinear regression), understandable statistics, and data organization. Designed for biological research applications in pharmacology, physiology, and other biological fields for data analysis, hypothesis testing, and modeling.
View all literature mentionsThis monoclonal targets Actin
View all literature mentionsThis polyclonal targets Iba1
View all literature mentionsThis monoclonal targets Synaptophysin 1
View all literature mentionsThis monoclonal targets beta-Amyloid 17-24
View all literature mentionsThis monoclonal targets Phospho-Tau (Ser202, Thr205)
View all literature mentionsThis monoclonal targets Phospho-Tau (Thr231)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser404)
View all literature mentionsThis monoclonal targets Phospho-Tau (Ser396)
View all literature mentionsThis polyclonal targets Human Tau, phospho (Thr217)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser262)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser214)
View all literature mentionsThis polyclonal targets Phospho-Tau (Thr205)
View all literature mentionsThis polyclonal targets Phospho-Tau (Thr212)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser199)
View all literature mentionsThis polyclonal targets DBN1
View all literature mentionsThis monoclonal targets Actin
View all literature mentionsThis polyclonal targets Iba1
View all literature mentionsThis polyclonal targets DBN1
View all literature mentionsThis monoclonal targets Synaptophysin 1
View all literature mentionsThis monoclonal targets Phospho-Tau (Thr231)
View all literature mentionsThis monoclonal targets beta-Amyloid 17-24
View all literature mentionsThis monoclonal targets Phospho-Tau (Ser202, Thr205)
View all literature mentionsThis monoclonal targets Phospho-Tau (Ser396)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser404)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser214)
View all literature mentionsThis polyclonal targets Human Tau, phospho (Thr217)
View all literature mentionsThis polyclonal targets Phospho-Tau (Thr212)
View all literature mentionsThis polyclonal targets Phospho-Tau (Thr205)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser199)
View all literature mentionsThis polyclonal targets Phospho-Tau (Ser262)
View all literature mentions